Drugs in Dev.
Immunology
Discovery
Japan 
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Discovery
Sponsor : PrecisionLife
Deal Size : Undisclosed
Deal Type : Partnership
Nxera Pharma and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic Area
Details : The strategic R&D partnership for the auto-immune disorders with the potential to identify new drug targets for the treatment of complex, chronic conditions.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 30, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery
Sponsor : PrecisionLife
Deal Size : Undisclosed
Deal Type : Partnership

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Discovery
Sponsor : AbbVie Inc
Deal Size : $409.0 million
Deal Type : Collaboration
Details : Sosei Heptares and AbbVie entered into the discovery collaboration and option-to-license agreement to discover, develop and commercialize novel small molecule medicines that modulate GPCR targets of interest to AbbVie.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $32.0 million
December 13, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery
Sponsor : AbbVie Inc
Deal Size : $409.0 million
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Discovery
Sponsor : AbbVie Inc
Deal Size : $409.0 million
Deal Type : Collaboration
Sosei Heptares and AbbVie Announce New Discovery Collaboration Targeting Inflammatory Diseases
Details : Sosei Heptares will apply its proprietary StaR® technology and GPCR-focused Structure-based Drug Design (SBDD) capabilities and fund R&D activities through the completion of Investigational New Drug (IND)-enabling studies.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $32.0 million
June 25, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery
Sponsor : AbbVie Inc
Deal Size : $409.0 million
Deal Type : Collaboration
